SAN FRANCISCO — Use of a functional scoring system dramatically reduced morphine treatment and length of stay among infants with neonatal abstinence syndrome (NAS) compared with the widely used ...

Although morphine is the drug almost exclusively used for neonatal abstinence syndrome (NAS), emerging data suggest that buprenorphine may be an acceptable and perhaps safer alternative. The two ...

Some researchers have used a more liberal definition of the neonatal abstinence syndrome that includes exposure to nonopioid substances. This can be problematic because the assessment tools for the ...

Each year in the US ∼50 000 neonates receive inpatient pharmacotherapy for the treatment of neonatal abstinence syndrome (NAS). The objective of this study is to compare the safety and efficacy of a ...

A quality improvement (QI) initiative that focused on using non-pharmacologic approaches to care for infants with neonatal abstinence syndrome (NAS) yielded positive short-term outcomes for both the ...

In the United States, one infant is born every 15 minutes with withdrawal symptoms after being exposed to opioids before birth, according to a new study published in the journal Pediatrics. And from ...

Methadone, a full mu-opioid agonist, is the recommended treatment for opioid dependence during pregnancy. However, prenatal exposure to methadone is associated with a neonatal abstinence syndrome (NAS ...

The long-term effects of neonatal abstinence syndrome (NAS) are not well known, but some research suggests it can continue to affect a child into adolescence. NAS refers to a group of conditions an ...